{"id":730,"date":"2001-05-01T12:05:00","date_gmt":"2001-05-01T10:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/blutdruckanstieg-durch-zyklooxygenase-2-inhibitoren"},"modified":"2001-05-01T12:05:00","modified_gmt":"2001-05-01T10:05:00","slug":"blutdruckanstieg-durch-zyklooxygenase-2-inhibitoren","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/blutdruckanstieg-durch-zyklooxygenase-2-inhibitoren","title":{"rendered":"Blutdruckanstieg durch Zyklooxygenase-2-Inhibitoren"},"content":{"rendered":"<p>Die neuen Zyklooxygenase-2-selektiven (COX-2-) Inhibitoren (Rofecoxib = Vioxx, Celecoxib = Celebrex) sind bei chronischen GeIenkerkrankungen \u00e4hnlich wirksam wie die herk\u00f6mmlichen nicht-steroidalen Antiphlogistika (NSAID). Ihr Vorteil besteht in einer geringeren gastrointestinalen Toxizit\u00e4t. Die vier- bis neunfach erh\u00f6hten Therapiekosten sind u.E. nur bei Patienten mit erh\u00f6htem Ulkusrisiko zu begr\u00fcnden (s.a. 1). Internisten aus der Mayo-Clinic berichten nun [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die neuen Zyklooxygenase-2-selektiven (COX-2-) Inhibitoren (Rofecoxib = Vioxx, Celecoxib = Celebrex) sind bei chronischen GeIenkerkrankungen \u00e4hnlich wirksam wie die herk\u00f6mmlichen nicht-steroidalen Antiphlogistika (NSAID). Ihr Vorteil besteht in einer geringeren gastrointestinalen Toxizit\u00e4t. Die vier- bis neunfach erh\u00f6hten Therapiekosten sind u.E. nur bei Patienten mit erh\u00f6htem Ulkusrisiko zu begr\u00fcnden (s.a. 1). Internisten aus der Mayo-Clinic berichten nun [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[324,1859,1860,1355,1360,325,564,562,563,565,1858,1350],"class_list":["post-730","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-blutdruck","tag-celecoxib","tag-class-studie","tag-cox-2-hemmer","tag-coxibe","tag-hypertonie","tag-nichtsteroidale-antiphlogistika","tag-nichtsteroidale-antirheumatika","tag-nsaid","tag-nsar","tag-rofecoxib","tag-zyklooxygenase-2-hemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=730"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/730\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}